Your Source for Venture Capital and Private Equity Financings

Endpoint Health Raises $52M

2022-06-02
PALO ALTO, CA, Endpoint Health today announced the close of $52 million in equity and debt financing.
Endpoint Health, a Precision-FirstTM therapeutics company dedicated to addressing unmet needs in immune-mediated acute and chronic diseases, today announced the close of $52 million in equity and debt financing. Major institutional investors participating in the Series A round included Mayfield, Humboldt Fund, AME Cloud Ventures, Boom Capital, Alix Ventures, Yaya Capital, Wireframe Ventures, The Venture Collective, HCX Ventures and Global Health Investment Corporation (GHIC).

Endpoint Health is a Precision-FirstTM therapeutics company dedicated to addressing unmet needs in immune-mediated acute and chronic diseases. We combine therapeutics, therapy-guiding tests, and AI to develop precision therapies for patients with immune-mediated conditions, such as acute respiratory distress syndrome (ARDS), sepsis, rheumatic and gastroenterologic diseases. Our vision is a world in which all patients get the best treatment possible for their unique biology and disease.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000 startups and 5,000 VC investors


Featured Reading